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Abstract
Purpose Medullary thyroid carcinoma (MTC) derives from the parafollicular C-cells of the thyroid gland. Somatostatin
receptors (SSTRs) are expressed in various neuroendocrine tumours including MTC. The aim of this study was to evaluate
SSTR2A as a prognostic factor for MTC, to study distribution of SSTR2A expression within tumours and to compare
expression of SSTR2A between primary tumours and corresponding lymph node metastases.
Methods Patients who underwent surgery between 1988 and 2014 for MTC from ﬁve tertiary referral centres in The
Netherlands were included. In total, primary tumours of 114 patients and lymph node metastases of 34 patients were
analysed for expression of SSTR2A using a tissue microarray, and correlated with clinicopathological variables and survival.
Results The mean age of patients was 45.5 years (SD 16.2), 55 patients were male (49.5%). Primary tumours of 58 patients
(50.9%) showed SSTR2A expression. In multivariate Cox-regression analysis, SSTR2A positivity correlated independently
with better overall survival (OS) (HR 0.3; 95% CI 0.1–1.0). In stage IV MTC patients, 10-year survival rates for SSTR2A-
negative and positive patients were 43% and 96%, respectively. In 53.9% of patients with lymph node metastases,
expression in primary tumour and lymph node metastases differed.
Conclusion SSTR2A expression is correlated with longer OS in MTC, especially for stage IV patients, suggesting that
SSTR2A expression might be a useful prognostic factor in MTC. The SSTR2A status of the primary MTC does not predict
expression in lymph node metastases.
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Introduction
Medullary thyroid carcinoma (MTC) is derived from the
parafollicular clear cells (C-cells) of the thyroid gland [1].
Although MTC accounts for only 4% of all thyroid carci-
nomas, it is accountable for about 13% of deaths resulting
from thyroid cancer [2]. Besides a sporadic form that occurs
in the majority of cases, MTC develops in the remaining
25–30% of patients as part of the hereditary tumour syn-
drome Multiple Endocrine Neoplasia type 2 (MEN2) [1].
Patients who are treated with curative intent should always
have a total thyroidectomy and dissection of the central
lymph node compartment. Adjuvant therapy in general is of
limited value [3–5]. Unfortunately, in more than 50% of
patients, calcitonin levels remain elevated after supposed
curative resection, indicating that subclinical active tumour
tissue is still present [3, 6].
Early diagnosis of MTC is very important to improve
prognosis. When diagnosed in an early phase (stage I and
II), 10-year survival rates are favourable at 100% and 93%,
respectively. Unfortunately, approximately 45% of patients
present with metastases (stage III and IV), associated with
10-year survival rates of 71% and 21%, respectively [3].
Prognosis is difﬁcult to predict in stage III or IV MTC,
whereas this is essential for personalised follow-up and
adjuvant therapy strategies for patients that will rapidly
progress [7].
The C-cells of the thyroid gland have the ability to
express somatostatin receptors (SSTRs) like many neu-
roendocrine tumours. There are six different subtypes:
SSTR1, SSTR2A, SSTR2B, SSTR3, SSTR4 and SSTR5
[8]. These receptors have a broad spectrum of biological
actions including inhibition of proliferation, cell-survival
and angiogenesis [8–10]. In this study, we focused on
SSTR2A since this particular receptor is used as a target for
nuclear imaging as well as for medical therapy. Expression
of SSTR2 enables the use of somatostatin analogues
(SSTA) for therapeutic purposes, which has a positive effect
on the symptoms accompanying MTC like diarrhoea,
weight loss and malaise [11–13]. Unfortunately SSTA
therapy does not reduce tumour mass, nor improve survival
rates [12]. Peptide receptor radionuclide therapy (PRRT)
with radioactively labelled SSTA shows promising results
in other endocrine tumours, with much higher response
rates than SSTA therapy. In a recent randomised phase 3
trial in patients with progressive midgut neuroendocrine
tumours, treatment with 177Lu-Dotatate resulted in a risk of
progression or death that was 79% lower than the risk
associated with a high-dose of the SSTA octreotide [14].
Limited information is available on the effect of PRRT with
SSTA in MTC. Only a few, small sample sized studies have
been conducted, but with promising results. Disease pro-
gression, stable disease and (partial) response was seen in
14–65%, 0–61% and 18–67% of patients, respectively.
Toxicity was low and quality of life improved using PRRT
[15–18]. To determine whether a patient is eligible for
treatment with PRRT, the receptor subtype and the amount
of expression in this speciﬁc tumour needs to be established
[15, 18]. This can be done by imaging using radioactive
SSTA or by immunohistochemistry on tumour tissue [11].
Currently, imaging modalities still have limitations in
identifying metastases, resulting in a low speciﬁcity and
sensitivity [3]. SSTR expression enables the use of SSTA
scans for follow-up in patients with persistent MTC for
localisation of metastases, especially in the neck lymph
nodes [12]. At this moment, stability of SSTR expression
between primary tumours and lymph node metastases is not
yet investigated in MTC. For the utility of SSTA scans,
such information is necessary.
Besides being useful as therapeutic target, SSTR
expression might be relevant as a prognostic factor. Herac
et al. [8]. studied the correlation between SSTR2A and
SSTR5 expression and several clinicopathological features.
They demonstrated a signiﬁcant correlation between
SSTR2A expression and the presence of lymph node
metastases, which is an indicator of poor prognosis, but no
survival analysis was presented [3, 8]. The aim of this study
was to evaluate SSTR2A as a prognostic factor in a larger
cohort of MTC patients with long-term follow-up. Fur-
thermore, we studied distribution of SSTR2A within
tumours and compared expression of SSTR2A between
primary tumours and corresponding lymph node metastases.
Materials and methods
Patients
Patients who underwent surgery between 1988 and 2014 for
MTC were identiﬁed from the pathology databases of Lei-
den University Medical Centre (LUMC), Amsterdam
Medical Centre (AMC), Radboud University Medical
Centre (RadboudUMC), University Medical Centre Gro-
ningen (UMCG) and University Medical Centre Utrecht
(UMCU), The Netherlands (all tertiary referral centres).
Formalin ﬁxed parafﬁn embedded (FFPE) tissues were
collected from the pathology archives. In total, 114 patients
were identiﬁed from whom primary tumour tissue was
available for inclusion in the tissue microarray (TMA).
From two of the ﬁve hospitals (LUMC and UMCU), tissue
of lymph node metastases was available as well, enabling
analysis of lymph node tissue of 34 patients.
Clinical and pathological patient information was
retrieved from patient ﬁles in all ﬁve centres. All MEN2
diagnoses were conﬁrmed by germline mutation analysis of
the RET gene. Sporadic patients were either patients with
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negative germline mutation analysis or with a negative
family history. Microscopic positive resection margins were
considered as part of the T-stage and not included as a
separate variable. Disease status was based on postoperative
(dichotomous) calcitonin and CEA serum values. No exact
values or doubling times were considered since we included
patients from ﬁve centres over almost three decades for
which different assays were applied at the time. An eleva-
tion in CEA or calcitonin was interpreted as persistent
disease, CEA or calcitonin within normal range was inter-
preted as cured. Only postoperative CEA and calcitonin
values that were measured > 6 months after surgery were
taken into account. Whole slides were scored for necrosis,
angioinvasion and desmoplasia. Necrosis and angioinvasion
were scored as absent or present and desmoplasia as
negative, some, moderate or severe. These scorings were
performed on the same FFPE blocks that were used for the
construction of the TMA.
This study was performed according to national guide-
lines with respect to the use of leftover tissue and approval
for this study, including the use of patient data, was
obtained from the Institutional Review Board of the UMCU
[7, 19].
Construction of tissue microarray
The TMA was constructed using an automated machine
(TMA grand master, 3D Histec, Budapest, Hungary). Three
cores of 0.6 mm were punched from each FFPE block of
primary tumour and lymph node metastases if available. To
assure that cores were punched from tumour areas, cell rich
areas were marked on H&E slides by a pathologist (P.v.D.
and L.L.), scanned, and marks were manually circled with
the TMA software (3D Histech).
Immunohistochemistry
The TMA blocks were cut at 4 µm and mounted on coated
slides. Staining for SSTR2A was carried out with an auto-
matic immunostainer (Bench Mark ULTRA Automated
IHC slide staining system, Ventana Medical Systems, Inc.,
USA) following protocol: after baking the slides at 75 °C
and incubating for eight minutes, the slides were depar-
afﬁnised on 72 °C. Antigen retrieval was performed using
the CC1 standard pre-treatment. The primary SSTR2A
antibody (1:20; code SS-8000-RM(A); rabbit IgG; biotrend)
was incubated for 32 min at 37 °C. Slides were counter-
stained with haematoxylin and coverslipped.
Scoring of immunohistochemistry
All cores in the SSTR2A TMA slides were scored by an
experienced pathologist (S.M.W.) and an experienced
researcher (L.L.) for staining intensity as absent (0), weak
(1), moderate (2) or strong (3) and percentage of positive
tumour cells. On the basis of Volante et al. [20], we con-
sidered only membranous staining positive and discarded
cytoplasmic staining. Representative scores of all immu-
nostainings are shown in Fig. 1. Data on hypoxia inducible
factor-1 alpha (HIF-1α), vascular endothelial growth factor
(VEGF), glucose transporter 1 (Glut-1), carbonic anhydrase
IX (CAIX) and microvessel density (MVD) was available
from a previous study [7].
Statistical analysis
Categorical data were summarised with frequencies and per-
centages, and continuous data were summarised with medians
and ranges. To increase the power of the statistical analysis
categorical data were recoded into dichotomous variables.
Grade of desmoplasia was recoded into none-some and
moderate-severe. Stage was recoded into stage I–III and stage
IV. Hereditability was recoded in either sporadic disease or
MEN2 syndrome [7]. SSTR2A scorings were transformed
into a dichotomous variable, being positive when the average
intensity of the three cores was ≥ 1, independently of the
previously scored percentage of staining.
Overall survival (OS) was deﬁned as the time to death
from any cause. Progression-free survival (PFS) was deﬁned
as the time to development of distant metastases or death.
Univariate Kaplan–Meier survival analysis was per-
formed and Kaplan–Meier survival curves were plotted.
Fig. 1 Representative examples of immunohistochemical staining for SSTR2A in TMA of MTC. a Absent SSTR2A staining. b SSTR2A staining
with intensity 1 in 10% of cells. c SSTR2A staining with intensity 2 in 100% of cells. d SSTR2A staining with intensity 3 in 60% of cells
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The log-rank test was used to calculate signiﬁcance. Mul-
tivariate Cox-regression analysis was performed and hazard
ratios (HR) of clinicopathological characteristics on OS
were calculated. All reported p-values were two sided.
Analysis was performed using SPSS version 24.0 software
(SPSS, Inc., Chicago, IL, USA).
Results
Clinicopathological variables
The 114 patients included in this study were between eight
and 82 years of age (mean age 45.5, SD 16.2). Fifty-ﬁve
patients were male (49.5%) and 56 (50.5%) were female (in
three cases gender was unknown). Sixty patients (57.7%)
had sporadic MTC, 40 patients (38.5%) had MEN2a and
four patients had MEN2b (3.8%) (in ten patients the
mutation status was unknown). Median tumour size ranged
from 4 to 70 mm (mean 26.1 mm). At the time of ﬁrst
surgery 68 patients (61.8%) presented with lymph node
metastases. Fifteen patients (14.4%) presented with stage I,
25 (24.0%) with stage II, 16 (15.4%) with stage III and 48
(46.2%) with stage IV (in ten patients tumour stage was
unknown). Mean follow-up time was 69.5 months (range
0–318 months).
SSTR2A expression in primary tumours
Sixty-ﬁve patients (57.0%) expressed SSTR2A in their
primary tumour, including weak expression (average
intensity ≥ 1) in 35 patients (30.7%), moderate expression
(average intensity ≥ 2) in 14 patients (12.3%) and strong
expression (average intensity 3) in nine patients (7.9%). In
the remaining seven patients (6.1%), so little expression
(average < 1) was seen that these patients were classiﬁed as
negative. In 49 patients (43.0%) there was no SSTR2A
expression present in the primary tumour. Figure 2 shows
the intensity of all scored cores in each patient individually
and demonstrates the distribution of different intensities
throughout the entire group of patients.
As to primary tumour distribution of SSTR2A expression,
ten patients had only one core and were discarded. Of the
remaining 104 patients, 72 (69.3%) showed homogeneous
expression and 32 (30.8%) showed heterogeneous expression.
SSTR2A expression in primary tumours vs. lymph
node metastases
The average SSTR2A intensity was 0.9 (SD 1.0) of all pri-
mary tumours (n= 114) and 0.7 (SD 1.1), 0.8 (SD 1.0) and
0.6 (SD 0.7) for lymph node metastases at initial presentation
and subsequent surgeries (not signiﬁcant).
Figure 3 shows the average expression within the various
tissues for each individual patient. Five patients (14.7%)
showed SSTR2A expression in both primary tumour and all
lymph node metastases, but with differences in intensity
levels between the primary tumour and lymph node metas-
tases in all ﬁve. Eleven patients (32.4%) showed no
SSTR2A expression at all in either tissue. Ten patients
(29.4%) did not express any SSTR2A in the primary tumour
but did show SSTR2A expression in ≥1 of the lymph node
metastases. Eight patients (23.5%) showed SSTR2A
expression in the primary tumour but no expression in ≥1 of
the lymph nodes metastases.
Association between primary tumour SSTR2A
expression and clinicopathological variables
Expression of SSTR2A in comparison with clin-
icopathological parameters is outlined in Table 1. Herit-
ability (MEN2) and HIF-1α were the only characteristics
0 1 2 3
Fig. 2 Intensity of all scored cores in each patient individually arran-
ged from low average intensity to high average intensity. Each bar
represents one patient. The length of the bar correlates with the amount
of cores scored per patient. The colours of the bars represent the
intensity of the staining. The patients on the left of the blue stripe are
SSTR2A negative, the patients on the right of the blue stripe are
SSTR2A positive
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Fig. 3 Average intensity of SSTR2A expression in primary tumour
and their subsequent lymph node metastases. The vertical axis shows
the average intensity of the staining. PT primary tumour, LNM lymph
node metastasis. *= p-value between average intensities calculated by
Wilcoxon Signed Ranks Test
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that were signiﬁcantly different between SSTR2A-negative
and positive groups with 34.1% vs. 65.9%, and 34.5% vs.
65.5%, respectively.
Prognostic value
As outlined in Table 2, for OS a signiﬁcant prognostic
association was found for SSTR2A expression, heritability,
stage, lymph node metastases, disease status, necrosis and
VEGF. Thirty-eight patients (80.9%) vs. 48 patients
(94.1%) survived in the SSTR2A-negative and SSTR2A-
positive groups, respectively, (p= 0.035). In the
Kaplan–Meier curves shown in Fig. 4 the prognostic effect
of SSTR2A positivity for all patients is shown, for patients
with stage I–III and for patients with stage IV. Within the
group of patients having stage IV MTC, 10-year survival
rates decrease signiﬁcantly in SSTR2A-negative patients;
from 96% for SSTR2A-positive patients to 43% for
SSTR2A-negative patients. In the small subpopulation of
patients with lymph node metastases, 10-year survival rates
decrease, although not signiﬁcantly, when SSTR2A is not
expressed in ≥1 of the lymph nodes; from 64% for patients
with ≥1 positive lymph node to 49% for patients with
negative lymph nodes as shown in Supplementary Fig. 1.
For PFS a signiﬁcant association was found for heritability,
stage, lymph node metastases, disease status, necrosis, HIF-
1α and Glut-1, but not for SSTR2A expression.
Twelve patients died, which restricted the number of
variables we could use in multivariate Cox-regression
analysis. We chose to include SSTR2A and stage,
because disease stage is currently the strongest prognostic
variable available. The variable heritability was left out of
multivariate Cox-regression analysis since in our study
almost all patients with hereditary tumours had stage I or II
MTC. This can be explained by the fact that the majority of
these patients had prophylactic thyroidectomies. Lymph
node metastasis were not included since this variable is also
taken into account when tumour stage is analysed. Disease
status was left out because this is predominantly based on
postoperative CEA/calcitonin measurements, which only
have meaning when evaluated over time, but not as a single
Table 1 Clinicopathological characteristics of MTC patients stratiﬁed
by SSTR2A intensity
SSTR2A
negative
SSTR2A
positive
p-value
N= 56 N= 58
Mean age in years (SD) 45.3 (16.7) 52 (15.8) 0.90
Gender 1.00
Male (%) 28 (50.9) 27 (49.1)
Female (%) 28 (50.0) 28 (50)
Heritability 0.01
Sporadic (%) 38 (63.3) 22 (36.7)
MEN2a/b (%) 15 (34.1) 29 (65.9)
Stage 0.56
I–III (%) 28 (51.9) 26 (48.1)
IV (%) 22 (45.8) 26 (54.2)
Mean size in mm (SD) 26.8 (14.4) 25.4 (15.7) 0.64
< 20 mm (%) 17 (45.9) 20 (54.1) 0.67
≥ 20 mm (%) 32 (52.5) 29 (47.5)
Lymph node metastasis 0.08
No (%) 26 (61.9) 16 (38.1)
Yes (%) 29 (42.6) 39 (57.4)
Overall survival 0.06
Did not die (%) 38 (44.2) 48 (55.8)
Died (%) 9 (75.0) 3 (25.0)
Progression-free survival (%) 0.41
No progression/death 40 (51.3) 38 (48.7)
Progression/death 12 (46.2) 14 (53.8)
Disease status 0.15
Normal CEA (%) 14 (37.8) 23 (62.2)
Elevated CEA (%) 33 (54.1) 28 (45.9)
Necrosis 1.00
Absent (%) 43 (47.8) 47 (52.2)
Present (%) 4 (44.4) 5 (55.6)
Angioinvasion 0.32
Absent (%) 44 (49.4) 45 (50.6)
Present (%) 3 (30.0) 7 (70.0)
Desmoplasia 0.23
None-some (%) 27 (54.0) 23 (46.0)
Moderate-severe (%) 20 (40.8) 29 (59.2)
HIF-1α 0.00
Negative (%) 30 (68.2) 14 (31.8)
Positive (%) 20 (34.5) 38 (65.5)
CAIX 0.43
Negative (%) 28 (52.8) 25 (47.2)
Positive (%) 21 (43.8) 27 (56.3)
Glut-1 0.21
Negative (%) 49 (51.0) 47 (49.0)
Positive (%) 1 (16.7) 5 (83.3)
MVD (SD) 14.5 (9.5) 13.9 (6.1) 0.72
Table 1 (continued)
SSTR2A
negative
SSTR2A
positive
p-value
N= 56 N= 58
< 14.3 vessels/core (%) 30 (53.6) 26 (46.4) 0.32
≥ 14.3 vessels/core (%) 19 (42.2) 26 (57.8)
VEGF 0.84
Negative (%) 17 (45.9) 20 (54.1)
Positive (%) 30 (49.2) 31 (50.8)
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Table 2 Univariate survival analysis on progression-free (PFS) and overall survival (OS) for MTC patients
Progression-free survival Overall survival
N PF (N) PF (%) p-value N OS (N) OS (%) p-value
SSTR2A 0.71 0.04
Negative 52 40 76.9 47 38 80.9
Positive 52 38 73.1 51 48 94.1
Gender 0.15 0.48
Male 51 35 68.6 48 41 85.4
Female 53 43 81.1 50 45 90.0
Heritability 0.01 0.00
Sporadic 56 39 69.9 52 42 80.8
MEN2a/b 44 37 84.1 42 41 97.6
Stage 0.00 0.02
I–III 53 51 96.2 50 48 96.0
IV 47 23 48.9 45 35 77.8
Size in mm 0.35 0.87
< 20 mm 36 31 86.1 36 33 91.7
≥ 20 mm 60 18 70.0 56 49 87.5
Lymph node metastasis 0.00 0.03
No 40 39 97.5 37 36 97.3
Yes 64 39 60.9 61 50 82.0
Disease status 0.00 0.01
Normal CEA/calcitonin 37 35 94.6 37 37 100.0
Elevated CEA/calcitonin 60 36 60.0 57 45 78.9
Necrosis 0.00 0.00
Absent 88 68 77.3 85 76 89.4
Present 9 3 33.3 7 4 57.1
Angioinvasion 0.11 0.85
Absent 87 66 75.9 83 72 86.7
Present 10 5 50.0 9 8 88.9
Desmoplasia 0.33 0.34
None-some 50 40 80.0 48 44 91.7
Moderate-severe 47 31 66.0 44 36 81.8
HIF-1α 0.00 0.06
Negative 42 39 90.7 41 39 95.1
Positive 57 22 61.4 54 44 81.5
CAIX 0.40 0.25
Negative 53 43 81.1 52 48 92.3
Positive 46 31 67.4 42 34 81.0
Glut-1 0.01 0.52
Negative 94 71 75.5 90 78 86.7
Positive 6 3 50.0 5 5 100.0
MVD 0.31 0.51
< 14.3 vessels/core 55 37 67.3 51 43 84.3
≥ 14.3 vessels/core 44 36 81.8 43 39 90.7
VEGF 0.65 0.03
Negative 37 26 70.3 34 32 94.1
Positive 59 46 78.0 57 47 82.5
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value. Since necrosis was only present in 11 patients
(7.9%), it is not suitable as a prognostic factor and was,
therefore, not included in the multivariate Cox-regression
analysis. Desmoplasia, HIF-1α, CAIX, Glut-1 and VEGF
were not taken into account since these are all pathological
variables while we wanted to see whether SSTR2A
expression could add something to the existing clinical
prognostic variables.
SSTR2A expression and stage signiﬁcantly and inde-
pendently correlated to OS, as outlined in Table 3. SSTR2A
expression ≥ 1 decreased the risk to die with a HR of 0.27
(95% conﬁdence interval (CI) 0.07–0.98). Having stage IV,
on the other hand, increased the risk of dying with a HR of
5.05 (95% CI 1.10–23.05).
Discussion
The aim of this study was to evaluate SSTR2A as a prog-
nostic factor for MTC, to study distribution of SSTR2A
expression within tumours and to compare expression of
SSTR2A between primary tumours and corresponding
lymph node metastases.
We found SSTR2A expression in 50.9% of MTC cases.
This is slightly less than the ﬁndings of Herac et al. [8] who
found SSTR2A expression in 66.0% of patients. Other
studies investigated SSTR2 expression in general, not
SSTR2A in particular. Zatelli et al. [12] and Papotti et al.
[21] studied SSTR2 expression in 51 patients and found
positivity in 22 patients (43%). Kendler et al. [22] recently
found SSTR2 expression in 12 of 42 studied patients
(28.6%). Taken together, approximately half of patients
seem to show SSTR2 expression.
In survival analysis, SSTR2A expression was indepen-
dently associated with better OS, especially in stage IV
patients. Therefore, SSTR2A expression might be a valu-
able prognostic marker in MTC. Interestingly, no associa-
tion was found for SSTR2A expression and PFS, for which
we do not have a good explanation. The more favourable
prognosis accompanying SSTR2A expression could be
explained by the fact that well differentiated tumours, which
still express SSTRs like normal C-cells, tend to have a more
indolent course of disease. Herac et al. [8] studied SSTR2A
expression in 97 patients with MTC and found that
SSTR2A expression could be an adverse prognostic factor
since it correlated with presence of lymph node metastases.
Herac et al. found that patients with lymph node metastases,
were SSTR2A positive in 92.0% and negative in 8.0%. In
our study, patients with lymph node metastases were
SSTR2A positive and negative in 57.4% and 42.6%,
respectively. So, in our study we also found the association
between lymph node metastases and SSTR2A expression,
however, contrary to Herac et al., in our study this asso-
ciation was not signiﬁcant. The variance in our results could
be explained by the fact that in the study of Herac et al.
25.8% had lymph node metastases at the time of primary
surgery, whereas in our study 61.8% of patients presented
with lymph node metastases [8].
Fig. 4 Kaplan–Meier overall survival curves for patients with SSTR2A-positive and negative MTC. a Analyses over total group of 114 patients. b
Analyses over subpopulation of TNM-stage I–III patients. c Analyses over subpopulation of TNM-stage IV patients
Table 3 Multivariate Cox-regression analysis on OS
Events/
patients
Adjusted hazard ratio (95%
CI)
p-value
SSTR2A 0.05
Negative 9/43 1
Positive 3/51 0.3 (0.1–1.0)
Stage 0.04
I–III 2/49 1
IV 10/45 5.0 (1.1–23.0)
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We show for the ﬁrst time that in the majority of MTC
cases the distribution of SSTRs was homogeneous
throughout the primary tumour. This implies that pre-
operatively identiﬁcation of the SSTR2A status on core
needle or ﬁne needle aspiration biopsies should be possible,
which has consequences for therapy strategies such as the
use of PRRT. Also in practice, one can imagine that by
knowing SSTR2A status of a patient who presents with
stage IV disease, the treating physician might be able to
give a better indication of prognosis.
Twenty-four percent of cases showed SSTR2A expres-
sion in the primary tumour, but not in ≥1 of the lymph node
metastases. Furthermore, 29.4% patients who did not show
expression in the primary tumour, expressed SSTR2A in ≥1
of the lymph node metastasis. This means that, based on our
immunohistochemistry ﬁndings, SSTR2A status of the
primary tumour is a poor predictor of expression in lymph
node metastases, which might indicate that the SSTR2A
status of the primary tumour cannot be used as a tool for
clinical decision making with regard to SSTR2A nuclear
imaging.
Herac et al. [8] found that desmoplasia, CAIX and HIF-
1α were signiﬁcantly correlated with SSTR2A expression.
In our study, we did not ﬁnd signiﬁcant associations with
desmoplasia and CAIX, but could conﬁrm the association
with HIF-1α. It is known that somatostatin and octreotide, a
SSTR2A-speciﬁc SSTA, can block the activation and
inhibit the effect of HIF-1α and its downstream targets [23,
24]. This ﬁnding suggests a relation between the two fac-
tors, even though the correlation is not fully understood yet
and this should be investigated on a cellular level.
One of the strengths of our retrospective study is the
large sample size, considering MTC has a low incidence.
Also, our follow-up time is long (mean 69.5 months, range
0–318 months). Long follow-up is essential since MTC is a
tumour with low proliferative activity and low event rates.
Furthermore, we used immunohistochemical data, which we
were able to combine with clinical endpoints such as the
occurrence of distant metastases and death. Limitations of
our study mainly are a consequence of the retrospective
design of it and the rare occurrence of MTC. In our data-
base, we included patients from ﬁve different tertiary
referral centres covering almost three decades. Therefore, in
our analysis we had to use variables that were consistent
over time and between centres. Since we included patients
from over almost three decades we have a wide range in our
follow-up period. Furthermore, guidelines for surgery have
changed over the years and surgical techniques may have
differed between centres, which may have resulted in not all
patients getting a cervical lymph node resection. This may
have caused an underestimation of lymph node-positive
patients. Moreover, one might argue that whole slide ana-
lysis would be a superior technique to TMA. However, in
previous studies, good concordance between TMA and
whole slide analysis was found if only one punch was used,
with an increasing level of concordance if more punches
were considered [25]. Furthermore, for the validation of
prognostic biomarkers, TMA is described as the standard
[26, 27].
In conclusion, our results show that SSTR2A may be a
valuable prognostic biomarker for MTC patients indicating
longer OS, especially in stage IV patients. Distribution
within the tumour was homogenous in the majority of cases,
indicating that preoperative SSTR2A status may be assessed
in core needle or ﬁne needle aspiration biopsies. SSTR2A
status of the primary MTC is a poor predictor of expression
in lymph node metastases.
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